Drake & Associates’s Idexx Laboratories IDXX Stock Holding History

Drake & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-419	Closed	-$212K	–	97
2024 Q3	$212K	Buy	+419	New	+$204K	0.07%	86

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Drake & Associates's IDXX Position: Q4 2024 in Review

Drake & Associates sold out of Idexx Laboratories (IDXX) in Q4 2024, closing a stake of 419 shares — an estimated $212K sold.

Drake & Associates first reported a position in IDXX in Q3 2024 and held it in 1 quarter. The position peaked at $212K in Q3 2024. 1,123 funds tracked by Wall St. Rank hold IDXX as of Q4 2024.

Drake & Associates reported no remaining Idexx Laboratories position as of Q4 2024 after selling out during the quarter.
Drake & Associates sold 419 Idexx Laboratories shares in Q4 2024, an estimated $212K.
Drake & Associates first reported a position in Idexx Laboratories in Q3 2024 and held it in 1 quarter.
Drake & Associates's Idexx Laboratories position peaked at $212K in Q3 2024.
1,123 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2024.

Based on Drake & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.